



SF 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dario NERI et al.

Examiner: Alana M. Harris

Serial No.: 09/194,356

Group Art Unit: 1642

Filed: September 2, 1999

Title: ANTIBODIES TO ED-B DOMAIN OF FIBRONECTIN, THEIR  
CONSTRUCTION AND USES

**NON-RESPONSIVE RESUBMISSION OF SLIDES**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Being filed herewith is another copy of the five page powerpoint illustration mentioned in the first full paragraph on page 7 of the reply of October 5, 2006. Also filed is a copy of a PTO date-stamped filing receipt showing that the five slides indeed were submitted to the PTO on October 5, 2006.

The examiner may wish to pay particular attention to the second slide showing how oncofetal fibronectin comes in two different isoforms, one derived from ED-B and the other derived from a domain different from ED-B.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



---

Anthony J. Zelano, Reg. No. 27,969  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0003

Date: January 4, 2007  
AJZ:hlw

K:\Ellis-3\Non-Responsive Resubmission.doc

SERIAL NO. 09/194,356

DOCKET NO. ELLIS-0003

FILED: September 2, 1999


APPLICANT(S) Dario NERI et al.

**THE PATENT AND TRADEMARK OFFICE STAMP HEREON ACKNOWLEDGES**

**RECEIPT OF THE FOLLOWING PAPERS:**

☐ FILED BY CERTIFICATE OF MAILING ON:

- |  |                 |
|--|-----------------|
| <input checked="" type="checkbox"/> FEES \$ 1200.00                            | Check No. 37961 |
| <input type="checkbox"/> MISSING PARTS RESPONSE W/DECL.                        |                 |
| <input checked="" type="checkbox"/> AMENDMENT                                  |                 |
| <input checked="" type="checkbox"/> RESPONSE <input type="checkbox"/> ELECTION |                 |
| <input type="checkbox"/> NOTICE OF APPEAL                                      |                 |
| <input type="checkbox"/> APPEAL BRIEF (TRIPPLICATE)                            |                 |
| <input type="checkbox"/> ASSIGNMENT  |                 |
| <input checked="" type="checkbox"/> EXTENSION OF TIME 3 MO(S)                  |                 |
| <input type="checkbox"/> PRIORITY DOCUMENT(S)                                  |                 |
| <input type="checkbox"/> VERIFIED STATEMENT(S) UNDER 37 C.F.R. 1.9 & 1.27      |                 |
| <input type="checkbox"/> CONTINUATION PROSECUTION APPLICATION (CPA)            |                 |



- |  |   |
|--|---|
| <input type="checkbox"/> STATEMENT OF USE                  | <input type="checkbox"/> SHEETS OF DRAWINGS     |
| <input type="checkbox"/> ISSUE FEE                         | <input type="checkbox"/> COPY OF MISSING PARTS  |
| <input type="checkbox"/> DECLARATION UNDER                 | <input type="checkbox"/> RENEWAL APPLICATION    |
| <input checked="" type="checkbox"/> INFORMATION DISCLOSURE | <input type="checkbox"/> LETTER TO DRAFTSMAN    |
| <input checked="" type="checkbox"/> PTO 1449 W/4 REFS.     | <input type="checkbox"/> STATUS INQUIRY         |
|  | <input type="checkbox"/> APPLICATION DATA SHEET |

OTHER Declaration Under 37 CFR 1.132, Five slides

Initials: AJZ/hlw

Date Filed: October 5, 2006




*[Handwritten signature]*

# **“NORMAL” FIBRONECTIN: A SCHEMATIC REPRESENTATION**




- ▮ Twelve type I repeats (each repeat is homologous and is made by ~45 aminoacids)
- Two type II repeats (each repeat is homologous and is made by ~60 aminoacids)
- Fifteen type III repeats (each repeat is homologous and is made by ~90 aminoacids)
- ◊ One region called III CS






IN THE "NORMAL" FIBRONECTIN MOLECULE  
THE ED-B DOMAIN IS NOT PRESENT



DO NOT BIND BECAUSE THE EPITOPES (▲) ARE "MASKED"

WHEN IN THE ONCOFETAL FIBRONECTIN (B<sup>+</sup> FIBRONECTIN TYPE)  
THE EDB DOMAIN IS PRESENT



THE EPITOPES ▲ FOR BC-1, CF-525 AND OAL-TFN-01 GET  
“UNMASKED” THUS BECOMING ACCESSIBLE FOR BINDING  
(Carnemolla *et al.*, 1992, J Biol Chem, 267, 24689-92)

HOWEVER THE ONLY ANTIBODIES DIRECTLY RECOGNIZING THE  
EDB ■ ARE THE ANTIBODIES DESCRIBED IN THIS PATENT  
SPECIFICATION

# THE FDC6 ANTIBODY RECOGNIZES ONCOFETAL FIBRONECTIN WITH GLYCOSYLATED III CS BUT NOT THE ONCOFETAL B<sup>+</sup> FIBRONECTIN OR THE EDB

(Matsuura et al, J. Bio.Chem., Vol. 263, no. 7, 3314-3322, 1988)

FDC6

